Fig. 1: Response to platinum-based chemotherapy in the first cohort of PDX. | Nature Communications

Fig. 1: Response to platinum-based chemotherapy in the first cohort of PDX.

From: Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Fig. 1

a Waterfall plot representing platinum response in 55 TNBC PDX. Each bar represents the median best average response of treated xenografts from a PDX model, after 6 weeks of treatment. (n = 4–13 xenografts/group, the precise number of xenografts for each PDX is available in the source data file). PD: progressive disease, SD: stable disease, PR: partial response, CR: complete response. b Tumour response to cisplatin in the HBCx-9 (complete response), HBCx-11 (partial response), HBCx-151 (stable disease) and the HBCx-39 (progressive disease) PDX. RTV: relative tumour volume. Mean +/− SD. HBCx-9: n = 11 and 10 mice in control and treated groups, respectively, HBCx-11: n = 11 and 9 mice in control and treated groups, respectively, HBCx-151: n = 5 mice/group, HBCx-39: n = 11 and 13 mice in control and treated groups, respectively. c Response rates according to cisplatin and carboplatin PDX treatment. d PDX response to platinum agents according to patients’ neo-adjuvant chemotherapy (AC: Adriamycin and cyclophosphamide; FEC = 5-Fu + epirubicin + cyclophosphamide; NAC: neo-adjuvant chemotherapy). e PDX response to platinum agents according to patients’ residual cancer burden (RCB) scores. f Kaplan–Meier survival curve with the Gehan–Breslow–Wilcoxon test for the overall survival rate of TNBC patients stratified by platinum response in the matched PDX.

Back to article page